tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Technology Stocks: Nvidia (NVDA), Cambium Networks (CMBM) and GoodRx Holdings (GDRX)

Analysts have been eager to weigh in on the Technology sector with new ratings on Nvidia (NVDAResearch Report), Cambium Networks (CMBMResearch Report) and GoodRx Holdings (GDRXResearch Report).

Nvidia (NVDA)

Jefferies analyst Mark Lipacis maintained a Buy rating on Nvidia yesterday and set a price target of $370.00. The company’s shares closed last Monday at $177.93.

According to TipRanks.com, Lipacis is a top 25 analyst with an average return of 29.1% and a 70.5% success rate. Lipacis covers the Technology sector, focusing on stocks such as Advanced Micro Devices, Smart Global Holdings, and NXP Semiconductors.

Nvidia has an analyst consensus of Strong Buy, with a price target consensus of $237.90, which is a 33.7% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $185.00 price target.

See today’s best-performing stocks on TipRanks >>

Cambium Networks (CMBM)

In a report released today, Christopher Howe from Barrington maintained a Hold rating on Cambium Networks. The company’s shares closed last Monday at $19.73.

According to TipRanks.com, Howe is a 5-star analyst with an average return of 12.6% and a 51.4% success rate. Howe covers the Industrial Goods sector, focusing on stocks such as Commercial Vehicle Group, Standex International, and Helios Technologies.

Cambium Networks has an analyst consensus of Moderate Buy, with a price target consensus of $27.75.

GoodRx Holdings (GDRX)

Jefferies analyst Glen Santangelo maintained a Buy rating on GoodRx Holdings yesterday and set a price target of $9.00. The company’s shares closed last Monday at $7.76, close to its 52-week low of $5.62.

According to TipRanks.com, Santangelo is a 5-star analyst with an average return of 16.5% and a 65.2% success rate. Santangelo covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, Health Catalyst, and Doximity.

Currently, the analyst consensus on GoodRx Holdings is a Hold with an average price target of $10.97, implying a 41.4% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $13.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NVDA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More